August 7, 2017 / 8:27 PM / 2 years ago

BRIEF-Cytomx Therapeutics Q2 loss per share $ 0.69​

Aug 7 (Reuters) - Cytomx Therapeutics Inc

* Cytomx announces second quarter 2017 financial results and mid-year update webcast conference call

* Q2 revenue $8.8 million versus $3.1 million

* Q2 revenue view $6.3 million — Thomson Reuters I/B/E/S

* Cytomx Therapeutics Inc - ‍as of June 30, 2017, Cytomx had cash, cash equivalents and short-term investments of $335.9 million​

* Cytomx Therapeutics- ‍based upon current operating plan, company expects its existing capital resources will be sufficient to fund operations into 2020​

* Cytomx Therapeutics Inc - ‍remain on track to disclose data from initial probody clinical trials in 2018​

* Cytomx Therapeutics Inc qtrly ‍net loss per share, basic and diluted $ 0.69​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below